Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN
Abstract
Aims: To evaluate the impact of iGlarLixi on the depth of glycaemic control, glycaemic variability (GV) and postprandial glucose (PPG) control versus insulin glargine 100 U/mL (iGlar) or lixisenatide (Lixi) in Asian Pacific individuals with type 2 diabetes (T2D).
Materials and methods: A post hoc analysis was conducted of two phase 3 trials in individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin (LixiLan-L-CN). Outcomes were evaluated from baseline to end-of-treatment (EOT; Week 24 or 30, respectively). Using self-monitoring of blood glucose (SMBG) profiles, glycaemic control depth was assessed via derived time in tight range (dTITR; 3.9-7.8 mmol/L). GV was evaluated using standard deviation (SD) of SMBG, high blood glucose index (HBGI), mean absolute glucose (MAG), and mean amplitude of glycaemic excursions (MAGE). PPG at 0.5, 1, and 2 h was measured via standardised meal tests.
Results: From baseline to EOT, iGlarLixi provided greater increases in dTITR versus iGlar (least squares mean difference 15.03%) or Lixi (29.14%) in LixiLan-O-AP, and versus iGlar (15.93%) in LixiLan-L-CN. At EOT, > 50% dTITR rate was 67.2%, 41.1% and 26.5% with iGlarLixi, iGlar and Lixi in LixiLan-O-AP, respectively, and 53.6% and 26.4% with iGlarLixi and iGlar in LixiLan-L-CN. iGlarLixi provided generally greater reductions in SD of SMBG, HBGI, MAG, MAGE and 0.5-, 1- and 2-h PPG versus iGlar or Lixi and greater 2-h PPG < 10.0 mmol/L achievement…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.